RT Journal Article
SR Electronic
T1 Sensitivity of BA.2.86 to prevailing neutralising antibody responses
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2023.09.02.556033
DO 10.1101/2023.09.02.556033
A1 Daniel J Sheward
A1 Yiqiu Yang
A1 Michelle Westerberg
A1 Sofia Öling
A1 Sandra Muschiol
A1 Kenta Sato
A1 Thomas P Peacock
A1 Gunilla B Karlsson Hedestam
A1 Jan Albert
A1 Ben Murrell
YR 2023
UL http://biorxiv.org/content/early/2023/09/04/2023.09.02.556033.abstract
AB A new SARS-CoV-2 variant, designated BA.2.86, has recently emerged with over 30 spike mutations relative to its parental BA.2, raising questions about its degree of resistance to neutralising antibodies. Using a spike-pseudotyped virus model we characterise neutralisation of BA.2.86 by clinically relevant monoclonal antibodies and by two cohorts of serum sampled from Stockholm, including both a recent cohort, and one sampled prior to the arrival of XBB in Sweden.Competing Interest StatementDJS is a consultant for AstraZeneca AB.